[On the uricosuric activity of etofylline clofibrate (author's transl)].
In a review study including altogether 5 clinical trials with a total of 221 hyperlipidaemic patients the influence of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, Duolip) treatment on serum uric acid level was investigated. 73 patients thereof, i.e., one-third of the hyperlipidaemic patients, had increased values of uric acid. In all studies a statistically significant and clinically relevant uricosuric activity was established.
D002994:Clofibrate / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D014527:Uric Acid / Q000097:blood*; D014528:Uricosuric Agents
D000960:Hypolipidemic Agents; D014528:Uricosuric Agents; C028764:etofylline clofibrate; D014527:Uric Acid; D002994:Clofibrate
Zur Frage der harnsäuresenkenden Wirkung von Etofyllinclofibrat.